References

  1. Nomenjanahary Rodrigue Emile Hasiniatsy, Leontine Rabarijaona, Florine Rafaramino. Evolution des aspects épidémiologique de cancer du col utérin dans le service oncologie d'Antananarivo, Madagascar. J Afr Cancer. 2011 Feb; 3(1): 3-7. PubMed | Google Scholar

  2. Ngomo KMJ, Belemembaogo E, Nzenze JR, Meye JF, Diallo I, Moung. Evaluation de la prise en charge des cancers du col de l'utérus par télé-cobalt au Centre Hospitalier de Libreville. Med Afr Noire. 2004 Nov; 5111: 579-584.. PubMed | Google Scholar

  3. Wong L C, Choo Y C, Choy D. Long term follow up of potentation of radiotherapy by platinium in advanced cervical cancer. Gynecol Oncol. 1989 Nov;35(2):159-63. PubMed | Google Scholar

  4. Choo YC, Choy TK, Wong LC, Ma HK. Potentiation of radiotherapy by cis dichlorodiammine platinum (II) in advanced cervical carcinoma. Gynecol Oncol. 1986 ; 23 : 94-100. PubMed | Google Scholar

  5. Tseng CJ, Chang CT, Lai CH, Soong YK, Hong JH, Tang SG, et al. A randomized trial of concurrent chemoradiotherapy versus radiotherapy in advanced carcinoma of the uterine cervix. Gynecol Oncol. 1997; 66: 52-8. PubMed | Google Scholar

  6. Rose PG, Bundy BN, Watkins EB, Thigpen JT and al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340; 15: 1144-1453. PubMed | Google Scholar

  7. Whitney CW, Sause W, Bundy BN, Maletano JH, Hannigan EV et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999; 17; 5:1339-1348. PubMed | Google Scholar

  8. Wong LC, Ngan HYS, Cheug ANY, Cheng DKL, Choy DTK. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol. 1999; 17; 7: 2055-60. PubMed | Google Scholar

  9. Morris M, Eifel PJ, Lu J, Grisby PW, Levenbck C, Stevens RE et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999 Apr 15; 340(15): 1137-43. PubMed | Google Scholar

  10. Bourhis J, Mornex F. Bases biologiques de la chimioradiothérapie. In: Mornex F MJ, Droz JP, Marty M, editor. Chimioradiothérapie concomitante : présent et futur. Paris: Elsevier, 1999. p. 17-27. Google Scholar

  11. Robert J. Bases pharmacologiques des associations radiothérapie-chimiothérapie.:Enjeux et médicaments utilisés. In: Lagrange JL, Pignol JP, Bensadoun RJ, editors. Optimisation de l'intensité thérapeutique: les associations radiothérapie-chimiothérapie. Paris: John Libbey Eurotext. 1997; 23-30. Google Scholar

  12. Favaudon V, Noel G. Biological basis for concomitant chemoradiotherapy in carcinomas. Bull Cancer. 2005 Dec; 92(12):1027-31. PubMed | Google Scholar

  13. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol. 2007 Feb; 4(2):86-100. PubMed | Google Scholar

  14. Peters WA, Lui PY, Barrett R, Gordon W, Stock R, Berek JF et al. Cisplatin, 5-Fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy : report of a phase III inter-group study: San Francisco, CA, USA. 30th annual meeting of the Society of Gynecologic Oncologists. 1999; 102-114. PubMed | Google Scholar

  15. Keys H, Gibbons SK. Optimal management of locally advanced cervical carcinoma. J Natl Cancer Inst Monogr. 1996; 21:89-92. PubMed | Google Scholar

  16. Ozsaran Z, Yalman D, Yurut V, Arsas A and al. Radiochemotherapy for patients with locally advanced cervical cancer: early results. Eur J Gynaecol Oncol. 2003; 24(2):191-4. PubMed | Google Scholar